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Abstract: Although peptide therapeutics have been explored for decades, the successful delivery
of potent peptides in vitro and in vivo remains challenging due to the poor stability, low cell
permeability, and off-target effects. We developed a redox sensitive polymer-based nanocomplex
which can efficiently and stably deliver the peptide drug melittin for cancer therapy. The nanocomplex
selectively targets cancer cells through lactobionic acid mediated endocytosis and releases melittin
intracellularly upon the trigger of elevated redox potential. In vivo study proved that the targeted
nanocomplex shows excellent potency in inhibiting tumor growth in a xenograft colon cancer mouse
model. Thus, the polymer/melittin nanocomplexes will provide a new approach for melittin based
cancer therapy.
Keywords: nanocomplex; targeted delivery; melittin; redox sensitive; cancer
Key Contribution: A polymer/melittin nanocomplex was developed to selectively deliver melittin
into cancer cells and release intracellularly due to the endogenous high redox potential. This redox
sensitive polymer/melittin nanocomplex will provide a new approach for melittin based cancer therapy.

1. Introduction
Peptide-based drugs, which usually have less than 50 amino acids, hold a high potential for
treating various diseases. Furthermore, some peptide-based drugs have successfully entered the
market, such as cyclosporine, which is routinely used after organ transplantation to reduce the activity
of the immune system [1]. Some peptides can also be utilized as a cytosolic agent. One of the most
well-established peptides is luteinizing hormone-releasing hormone agonists for the combination
treatment of prostate cancer combined with radiation or chemotherapy [2,3]. The last decade has
witnessed the exponential growth of many peptide drugs entering clinical trials [4]. Specifically,
peptides hold many advantages for anticancer medications due to their high potency and a broad
range of targets. However, many hurdles, including vulnerability toward proteolytic digestion and
side effects due to off-targeting, have yet to be overcome [5–7]. For instance, the available cyclosporine
preparations showed a low bioavailability, high variation between patients, and the inability to obtain
both effective and safe doses [1].
Recently, melittin, a natural peptide from bee venom composed of 26 amino acids, has attracted a lot
of attention due to its anti-arthritis, anti-inflammatory, anticancer, and neuroprotective properties [8–13].
Melittin self-assembles into toroidal structures and induces the formation of pores on the cell membrane,
which ultimately results in cell death [14,15]. This unique cytolytic feature makes it impossible for cancer
cells to develop drug resistance. Due to the same reason, the non-specific cytolytic activity of melittin
could result in severe off-target effects, such as hemolysis (lysis of red blood cells), when administrated
intravenously. To make melittin druggable and safer, many approaches have been explored through
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Figure 1. Delivery pathway of targeted melittin nanocomplex for cancer therapy.

2. Results and Discussion
Figure 1. Delivery pathway of targeted melittin nanocomplex for cancer therapy.

2.1. Design and Synthesis of Polymer LBA-PDAPEG
In our recent work, we prepared an environment-sensitive peptide delivery system, dual secured
nano-sting through the combination of a zwitterionic glycol chitosan and disulfide bond [21]. In that
design, melittin was successfully delivered into cytosol and released under the acidic pH and high
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2. The synthesis scheme of LBA-PDAPEG.
LBA-PDAPEG.
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The composition of amine to carboxylic acid group determines the isoelectric point (IEP) of
polymer, which can be tuned by varying the feeding ratio of cysteamine to 3-mercaptopropionic acid.
The IEP points of polymers ranged from 9.5 to 5.0 when the cysteamine to 3-mercaptopropionic acid was
fed from 4/1 to 1/4 (Figure 4). The wide range of tunable surface charge of the polymers would allow for
the binding of peptides with different IEPs. The gentle electrostatic force between polymer and peptide
would prevent the potential denature of peptide if prepared with the traditional encapsulation method
accompanied with high intensive mechanical force or heat. In our study, we used a PDAPEG derivative
with a surface charge around −11 mV at the pH of 7.4 for nanocomplex fabrication. The targeting
moiety of LBA was conjugated to the amine group of through N-hydroxysuccinimide (NHS) and
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1-thyl-3-(3-(dimethylamino)propyl) carbodiimide (EDC) reaction. The conjugation was quantitatively
determined by the reduction of amine amount through a 2,4,6-trinitrobenzene sulfonic acid (TNBSA)
assay. The unmodified PDAPEG was determined to have 500 nmol pyridine rings per 1 mg polymer
with the co-incubation with 10 mM dithiothreitol (DTT). After the modification of both by cysteamine
and mercaptopropionic acid, the total amine amount was increased to 40.6 nmol per mg polymer.
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1 H-NMR of polymer PDAPEG-COOH, PDAPEG-NH , and PDAPEG in CDCl .
1H-NMR of polymer PDAPEG-COOH, PDAPEG-NH22, and PDAPEG in CDCl33.
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The conjugation was quantitatively determined by the reduction of amine amount through a 2,4,6trinitrobenzene sulfonic acid (TNBSA) assay. The unmodified PDAPEG was determined to have 500
nmol pyridine rings per 1 mg polymer with the co-incubation with 10 mM dithiothreitol (DTT). After
the modification of both by cysteamine and mercaptopropionic acid, the total amine amount was
increased to 40.6 nmol per mg polymer. After the conjugation of LBA, the available amine was
decreased to 32.5 nmol per mg polymer, which indicates a successful conjugation of LBA.

δ-potential (mV)

10
0

2.5
Toxins 2020, 12, 582
Toxins 2020, 12, x-10
FOR PEER REVIEW

4.5

6.5

8.5
pH

PDAPEG (NH2:COOH-4:1)
PDAPEG (NH2:COOH-1:1)
PDAPEG (NH2:COOH=1:2)
PDAPEG (No modification)

-20
30
-30

10.5
5 of 13
5 of 14

PDAPEG (NH2:COOH-1:4)
PDAPEG (NH2:COOH=2:1)
PDA-co-PEG-COOH
PDAPEG-NH2

20

Figure 4. The surface charges of PDAPEG-NH2/PDAPEG-COOH at different amine to carboxylate
ratio responsive to environmental pH.
δ-potential (mV)

10

2.2. Particle Characterization
0

Through electrostatic
complexation,
a negatively
charged PDAPEG
derivative
2.5
4.5
6.5
8.5
10.5 formed with
complexed positively charged peptide melittin at physiology pH and further condensed it. After the
pH
-10
formation of complex, melittin was entrapped within the network of nano-structure and was
protected through the outlayer hydration of PEG. The nanocomplex showed a particle hydrodynamic
-20
size of 357 ± 30
nm (Figure 5). They were almost spherical according to transmittance electron
microscopy. In addition, the surface charge of nanocomplex dropped from −11.8 ± 0.64 to −4.24 ± 0.21
-30 the successful complexation with melittin. This proper size would allow for the
mV also indicates
passive
transportation
of charges
nanoparticles
entering cancer cells through
enhanced
Figure
4. The
The surface
surface
of PDAPEG-NH2/PDAPEG-COOH
PDAPEG-NH2/PDAPEG-COOH
atdifferent
different
aminepermeability
to carboxylate
carboxylateand
Figure
4.
charges of
at
amine
to
retention
[31]. to
ratioeffect
responsive
to environmental
environmental pH.
pH.
ratio
responsive
2.2. Particle Characterization
A

B

Intensity

Through electrostatic complexation, a negatively charged PDAPEG derivative formed with
20
20
complexed positively charged peptide melittin at physiology pH and further condensed it. After the
formation of complex, melittin was entrapped within the network of nano-structure and was
15
15
protected through the outlayer hydration of PEG. The nanocomplex showed a particle hydrodynamic
size of 357 ± 30 nm (Figure 5). They were almost spherical according to transmittance electron
10
10
microscopy. In addition,
the surface charge of nanocomplex dropped from −11.8 ± 0.64 to −4.24 ± 0.21
mV also indicates the successful complexation with melittin. This proper size would allow for the
55
passive transportation of nanoparticles entering cancer cells through enhanced permeability and
retention effect [31].
00

10

A

100

1000

Size (d. nm)

B

Intensity

Figure 5. Characterization
of the nanocomplexes. Hydrodynamic size of nanocomplex in TBS buffer
20
20
Figure
5. Characterization
of the
nanocomplexes.
Hydrodynamic
size of nanocomplex
in bar
TBSin
buffer
measured
by dynamic light
scattering
(A) and TEM
image of nanocomplex
(B). Scale
(B) is
measured
light scattering (A) and TEM image of nanocomplex (B). Scale bar in (B) is 200
200 nm. by dynamic
15
15
nm.

2.3. High Redox Potential Environment Could Trigger the Release of Melittin

10 Environment Could Trigger the Release of Melittin
2.3. High
Redox Potential
A unique
feature of
intercellular environment is its high reduction potential due to the elevated
10

GSH,
an5 important
role in maintaining the reducing environment to prevent the excessive
A which
uniqueplays
feature
5 of intercellular environment is its high reduction potential due to the elevated
oxidation
stress
from
activities
as electron transfer
from respiration
or photosynthesis
[32].
GSH,
which
plays
annormal
important
rolesuch
in maintaining
the reducing
environment
to prevent the
Our
polymer
LBA-PDAPEG
would
be
almost
neutral
after
exposing
it
to
a
high
reduction
environment
excessive oxidation 00stress from normal activities such as electron transfer from respiration or
due to the lost functionalization of carboxylate
group and amine group. Thus, the complex would be
1000
100
10
dissociated quickly and would release
melittin
Size (d.
nm) accordingly. To evaluate how the complex responds
to a high GSH environment, fluorescence resonance energy transfer (FRET) based nanocomplex was
prepared as described, using Cy3 as energy donor and Cy5 as energy receptor. Excited at 530 nm of
Figure 5. Characterization of the nanocomplexes. Hydrodynamic size of nanocomplex in TBS buffer
Cy3, the energy was transferred from PDAPEG-Cy3 (donor) to melittin-Cy5 (acceptor), which led to
measured by dynamic light scattering (A) and TEM image of nanocomplex (B). Scale bar in (B) is 200
an increased emission intensity at 670 nm. A reducing environment, such as 10 mM DTT, was able
nm.
to cleave carboxylate groups. The dissociation of neutral polymer and positive melittin led to a
decreased energy transfer, which decreased the fluorescence intensity at 660 nm as shown in Figure 6.
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nm as shown in Figure 6. The fluorescence intensity was reduced by 20% after 50 min incubation with
DTT, suggesting that the nanocomplex integrity was partially compromised by a high reducing
Toxins
2020, 12, 582
6 of 13
environment.
A

B

F660/F560*10

1.6
1.4

0.6
0.4
0.2
0.0

10

20

30
40
Time (min)

50

60

Figure 6. The measured FRET intensities of nanocomplex with or without DTT as a function of time
Figure 6. The measured FRET intensities of nanocomplex with or without DTT as a function of time
(A) and full spectrum of complex with or without DTT when measured the FRET intensity (B).
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Figure 7. Hemolytic activity of melittin and nanocomplex. (A) The hemolytic activity of
Figure 7. Hemolytic activity of melittin and nanocomplex. (A) The hemolytic activity of
PDAPEG/melittin nanocomplexes of different polymer to melittin ratios. (B) The hemolytic activity of
PDAPEG/melittin nanocomplexes of different polymer to melittin ratios. (B) The hemolytic activity
melittin, PDA-PEG, and PDAPEG/melittin nanocomplexes in different pH and reducing environments.
of melittin, PDA-PEG, and PDAPEG/melittin nanocomplexes in different pH and reducing
*** p < 0.001, **** p < 0.0001.
environments. *** p < 0.001, **** p < 0.0001.

2.5. In vitro Cellular Uptake
2.5. In vitro Cellular Uptake
It has been reported that LBA can bind to cancer cells membrane overexpressed D-galactose
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red fluorescent (Figure 8). This data indicated that LBA could serve as a targeting moiety toward
HCT 116 colon cells. A similar LBA based targeting effect was also observed in the MCF-7 cells (data
not shown).
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2.6. In vitro Anticancer Activities
The cytotoxicity of nanocomplex was investigated toward various cancer cells, including HCT
116 and MCF-7 cells, as shown in Figure 9. Compared with free melittin, non-targeted nanocomplex
showed a similar effect at low concentration but less effective at concentration higher than 1 µM in
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Figure 9. Cytotoxicity of melittin, control nanocomplex, and LBA-nanocomplex for various cancer
cells. Cells were incubated with melittin nanocomplex and LBA-nanocomplex at melittin concentration
cells. Cells were incubated with melittin nanocomplex and LBA-nanocomplex at melittin
from 0.1 to 10 µM for 24 h. Data represent mean ± SD, (A) HCT 116 cell; (B) MCF-7 cells; (C) Polymer
concentration from 0.1 to 10 µM for 24 h. Data represent mean ± SD, (A) HCT 116 cell; (B) MCF-7 cells;
cytotoxicity for HCT-116 and MCT-7 cells. * p < 0.05, ** p < 0.01, *** p < 0.001.
(C) Polymer cytotoxicity for HCT-116 and MCT-7 cells. * p < 0.05, ** p< 0.01, *** p < 0.001.
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(Hercules, CA). HCT 116 human colorectal cancer cells and MCF-7 breast cancer cells were obtained
4.2. Preparation of Melittin Polymer
from American Type Culture Collection (ATCC).
PDA (2(pyridine-2-yldisulfanyl)ethyl acrylate) was synthesized with using aldrithiol-2
4.2.
of Melittin
andPreparation
mercaptoethanol
asPolymer
described [23]. PDA was then copolymerized with poly (ethylene
glycol) methacrylate at 1:1 ratio through AIBN initiated free radical polymerization to obtain
PDA (2(pyridine-2-yldisulfanyl)ethyl acrylate) was synthesized with using aldrithiol-2 and
poly[((2-(pyridin-2-yldisulfanyl)ethyl)acrylamide) co-[poly(ethylene glycol)]] (PDA-PEG).
mercaptoethanol as described [23]. PDA was then copolymerized with poly (ethylene glycol)
In order to produce PDA-PEG polymer with different amounts of amine and carboxylate
methacrylate at 1:1 ratio through AIBN initiated free radical polymerization to obtain poly[((2groups, cysteamine and 3-mercaptopropionic acid were conjugated to PDA-PEG at different ratios
(pyridin-2-yldisulfanyl)ethyl)acrylamide) co-[poly(ethylene glycol)]] (PDA-PEG).
(amine/carboxylate, molar ratio) through the thiol-disulfide exchange reaction (Figure 2), and the
In order to produce PDA-PEG polymer with different amounts of amine and carboxylate groups,
cysteamine and 3-mercaptopropionic acid were conjugated to PDA-PEG at different ratios
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resultant products were purified three times by precipitation in cold ether. Different feeding ratios
between cysteamine and 3-mercaptopropionic acid yield polymers with different isoelectric points (IEP).
LBA functionalization was carried out through EDC/NHS reaction. LBA was first activated with
EDC/NHS in 0.1M MES buffer at pH 6.0 for 30 min, and then polymer PDA-PEG with modification of
amine groups dissolved in PBS 7.4 at 20 mg/mL was added. The mixture was allowed to react overnight
at room temperature. Free LBA was removed by repeated dialysis using Spectra/Por® dialysis tube
(MWCO, 3.5 KDa) against dd H2 O for 48 h. Purified polymer was freeze-dried and stored at −20 ◦ C.
The pyridine concentration in the polymer was quantitatively determined by measuring the UV
absorbance at 375 nm after the cleavage by DTT. The concentration of pyridine was calculated based
on the extinction coefficient for pyridine-2-thione in DMSO at 375 nm (8080 M−1 cm−1 ). The molecular
weight of polymers was determined by GPC Viscotek GPCmax VE 2001 GPC solvent/sample
module equipped with Viscotek VE 3580 RI detector and 270 Dual Detector (Malvern Instruments,
Worcestershire, United Kingdom) using THF as mobile phase, and the structure composition was
determined by 1 H-NMR. The success conjugation of 3-mercaptopropionic acid or cysteamine was
confirmed by 1 H-NMR (Bruker Avance III HD 300, Billerica, MA, USA) and with a UV-vis spectrometer
(Beckman, DU650, Brea, CA, USA). The conjugation efficiency of LBA to PDA-PEG was quantified by
a 2,4,6-trinitrobenzene sulfonic acid (TNBSA) assay using cysteamine hydrochloride as standard.
4.3. FRET Measurement
The donor fluorescence dye Cy3-NHS was chemically conjugated with PDA-PEG, and the receptor
fluorescence dye Sulfo-Cy5-NHS was conjugated with melittin following our published method [29].
Cy3 labeled polymer and Cy5 labeled melittin were mixed to prepared nanocomplex. Samples were
loaded into Corning® 96 well black flat bottom plates and DTT was added to wells to cleave disulfide
bonds. Samples were excited at 500 nm with the cutting off at 530 nm. The entire fluorescence spectrum
(from 530 nm to 750 nm) of the complex treated prior to and after DTT was then recorded as a function
of the time with the help of a SpectraMax M5 Multi-Mode Microplate Reader (Molecular Devices,
San Jose, CA, USA).
4.4. Hemolysis Experiment
Rat whole blood was purchased from Bioreclamation (Hicksville, NY, USA). Red blood cells were
washed with 150 mM NaCl and centrifuged at 300 rcf for 2 min until the supernatant became clear.
The resulting red blood cells were suspended in PBS 7.4. Polymer complex or melittin was dispersed in
different buffers at a series of concentrations from 0.1 µM to 5 µM. To mimic the physiological condition,
nanocomplexes were dispersed in PBS 7.4 100 mM or PBS 5.0 100 mM. To mimic the intracellular
condition, nanocomplexes were dispersed in 150 mM PBS + 10 mM GSH and incubated at 37 ◦ C for 2 h.
Melittin nanocomplex or melittin solution was incubated with above red blood cells for 1 h at 37 ◦ C.
The release of hemoglobin was quantified by measuring the absorbance at 405 nm of the supernatant in
a microplate reader (ELX808, BioTek Instrument, Winooski, VT, USA) after centrifugation at 300 rcf. for
2 min. PBS and ddH2 O treated RBCs were used as negative control and positive control, respectively.
The degree of hemolytic was calculated as the following formula: hemolysis % = (Abs(test) − Abs(PBS
negative control))/Abs(DI water positive control)) × 100%.
4.5. Cellular Uptake
HCT 116 colon cancer and MCF-7 breast cancer cells were cultured in Dulbecco’s modification
of Eagle’s medium (Corning, Glendale, AZ, USA) supplemented with 10% FBS and 1%
penicillin–streptomycin (Life Technology, Grand Island, NY, USA) at 37 ◦ C in 5% humidified CO2
atmosphere. Cells were seeded in 35 mm Petri dishes with a density of 200,000 cells/petri dish and
allowed to grow overnight. Both non-targeting and targeting nano-complexes were applied to cells at
the Cy3 concentration of 2 µM for 3 h. Cells were washed three times with PBS and fixed with 4%
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formaldehyde, followed by staining with Hoechst 33,342 for 15 min. The cells were imaged with a
confocal laser scanning microscope (LSM 700, Zeiss, Oberkochen, Germany).
4.6. In Vitro Cytotoxicity
HCT 116 and MCF-7 cells were seeded in 96-well plates at the density of 20,000 cells/well and
incubated at 37 ◦ C in 5% CO2 overnight. Melittin, non-targeted complex, or targeted complex were
diluted with a complete medium at desired concentrations ranging from 0.1 to 10 µM. After 24 h of
incubation, the media were replaced with 100 µL fresh media containing 1 mg/mL MTT reagent and
incubated for 4 h. The formed MTT crystal was dissolved with a stop solution, and the final optical
density of the medium was measured using a microplate reader (ELX808, BioTek Instrument, Inc.,
Winooski, VT, USA) at λ = 595 nm.
4.7. Tumor Growth Retardation Study
Female nude mice were purchased from the Jackson lab and randomly assigned into 3 groups
(3 mice/group). All animal experiments were conducted in accordance with NIH regulations and
approved by the Institutional Animal Care and Use Committee of the University of South Carolina
(Protocol No. 100851, approval date: 23 September 2015). Total 5 million HCT 116 cells suspended in
PBS were subcutaneously injected into mice. When the tumor volume reached about 30 mm3 , the mice
were anesthetized with 3% of isoflurane and treated with LBA melittin nanoparticle at 2 mg/kg via
intratumoral injection. For control groups, the same amount of buffer used in preparing complex or
non-targeted nanoparticles was employed.
4.8. Statistics Analysis
Data was expressed as mean ± standard deviation and was analyzed using Microsoft Excel
and GraphPad Prism 6.0 (San Diego, CA, USA). Statistical analysis was performed using a one-way
Analysis of Variation (ANOVA) among treatment groups and the control group. A p value < 0.05 was
considered significant.
Author Contributions: Conceptualization, P.X.; methodology, B.C. and P.X.; software, B.C.; validation, B.C. and
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